Introduction
============

Plasma cell tumours are lymphoid B-cell neoplasms that are composed of plasma cells. These tumours may develop in a disseminated manner, affecting numerous bones (multiple myeloma), or, more rarely, as a solitary lesion in a single bone (solitary bone medullary plasmacytoma) or soft tissue \[extramedullary/extraosseous plasmacytoma (EOP)\]. EOP is uncommon, accounting for \~5% of all plasma cell neoplasms, and arises outside of the bone marrow, unaccompanied by any clinical evidence of existing multiple myeloma. The median age at diagnosis is \~55 years, and approximately two out of three patients are male ([@b1-mco-0-0-1417],[@b2-mco-0-0-1417]). In \~80% of cases of EOP, the neoplasm arises in the upper respiratory tract, including the oropharynx, nasopharynx, and sinuses; however, EOP may be located at various other sites, such as the lymph nodes, bladder, digestive system, breast, thyroid, central nervous system, and skin ([@b1-mco-0-0-1417]).

The clinical manifestations and symptoms of EOP, where present, are non-specific, as these depend on the location of the tumour. EOP manifests as a sessile or pediculate outgrowth, which may be either circumscribed or infiltrating ([@b1-mco-0-0-1417],[@b2-mco-0-0-1417]). Following the diagnosis of the tumour locally, it is necessary to exclude the existence of any systemic processes in order to confirm the diagnosis of EOP. Following treatment, \~70% of patients remain in complete remission for at least 10 years. However, in \~25% of cases, regional recurrences eventually develop, and metastasis to distant extraosseous sites also occurs occasionally ([@b2-mco-0-0-1417]). The present report provides a literature review of cases of parotid plasmacytoma published up until 2016, in addition to a presentation of one new clinical case taken from the personal experience of the authors.

Case report
===========

A 47-year-old man was referred to the Maxillofacial Surgery Clinic at Virgen del Rocio University Hospital (Seville, Spain) in January 2015, with a 3-month history of a painless lesion in the retroauricular area that had gradually increased in size. The patient reported a medical history that included arterial hypertension and sacrococcygeal trauma. Physical examination revealed a 3×3-cm, lobulated mass in the right parotid area, which was moderately tender upon palpation ([Fig. 1](#f1-mco-0-0-1417){ref-type="fig"}). The facial nerve was intact, and there was no evidence of palpable cervical lymph nodes. Clinical examination was otherwise non-contributory.

On ultrasound, a mass of reduced echogenicity was detected, without any evidence of cervical lymph node enlargement. Magnetic resonance imaging of the head and neck revealed a right parotid tail mass in the superficial portion of the right parotid gland. The mass measured 3×3×3 cm, was round with well-defined contours, and appeared hypointense on T1 and T2 sequences, and hyperintense on T2-short tau inversion recovery sequences ([Fig. 2](#f2-mco-0-0-1417){ref-type="fig"}). Ultrasonographically guided fine-needle aspiration cytology was performed, and the subsequent cytological analysis demonstrated diffuse infiltration of neoplastic large monoclonal plasmacytes with variable pleomorphism. This finding was suggestive of a lymphoproliferative lesion. Under general anaesthesia, a superficial parotidectomy was performed, following which the patient had an uneventful course and was discharged on the third postoperative day, and followed up at the outpatient clinic. Evaluation of the parotid gland was subsequently performed. The histological examination of tissue sections stained with haematoxylin and eosin showing an intraglandular lymph node with a diffuse plasmacytic proliferation among residual reactive lymphoid follicles, with minimal pleomorphism (some large nuclei and binucleated cells) ([Fig. 3](#f3-mco-0-0-1417){ref-type="fig"}). An immunohistochemical study revealed monotypic λ light chain restriction, as well as nuclear immunostaining for cyclin D1 ([Figs. 4](#f4-mco-0-0-1417){ref-type="fig"} and [5](#f5-mco-0-0-1417){ref-type="fig"}), and aberrant expression of CD10 (positive expression, which is not associated with the specific cell type). CD56 was found to be negative. No monocytic or marginal lymphoid proliferation was observed; therefore, a diagnosis of cyclin D1-positive, λ plasmacytic plasmacytoma was determined.

To differentiate between plasmacytoma and myeloma, a systemic workup was performed. A skeletal radiographic survey revealed no evidence of extraoral involvement on computed tomography of the chest, abdomen, or pelvis; and positron emission tomography with 18F-fludeoxyglucose (FDG) showed a hypermetabolic lesion (standardised uptake value, 3.9) with a soft tissue component in the right cervical area, which coincided with the parotid tail mass detected on the ultrasound study. No FDG-avid lymphadenopathy or distant metastasis was detected. A bone marrow biopsy was negative for malignancy, and laboratory analysis did not reveal anaemia, hypercalcaemia or renal involvement. Assays for Bence-Jones protein in the urine and for serum myeloma protein were negative. A final diagnosis of primary extraosseous/extramedullary plasmacytoma was made. Due to the aggressive nature of the disease, postoperative radiotherapy of the parotid region and neck, including the supraclavicular lymph node area, was performed, with a total dose of 30 Gy. The patient has been followed-up closely for 2 years, during which time he has remained completely devoid of any clinical symptoms, and shows no evidence of recurrence of the parotid tumour.

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Discussion
==========

For the present study, a literature search of Medline/PubMed (<http://www.ncbi.nlm.nih.gov/pubMed>) that included articles published up to June 2016 was conducted using the search term 'parotid plasmacytoma'. The inclusion criteria were as follows: English language articles identified in the Medline database, containing at least one case of plasmacytoma located in the parotid gland, along with detailed clinical, diagnostic or therapeutic criteria. The search revealed 18 papers, encompassing a total of 19 cases, that met these criteria. In total, 20 patients with plasmacytoma in the parotid gland were evaluated, including the 19 clinical cases taken from the literature, and the new clinical case presented in the current study ([Table I](#tI-mco-0-0-1417){ref-type="table"}). The mean age of the patients at the time of diagnosis, excluding the present case case, was 65.1±10.9 years (range, 38--78 years). The cases comprised 10 female patients (52.6%) and 9 male patients (47.4%), with parotid plasmacytoma located unilaterally in all cases: 10 patients showed left-side involvement, while 9 cases exhibited right-side involvement. The most frequent signs and symptoms were pain and swelling on the ipsilateral side. Treatment included chemotherapy in 3 cases, radiotherapy in 11 cases, and surgical removal in 15 cases.

A plasmacytoma is a solitary mass of neoplastic monoclonal plasma cells, which can arise in any area of the body. EOP arises from the plasma cells located in areas of soft tissue, whereas solitary bone medullary plasmacytoma arises from plasma cells located in the bone marrow. These two forms of disease represent different groups of neoplasms with regard to location, tumour progression, and overall survival rate ([@b1-mco-0-0-1417],[@b2-mco-0-0-1417]). The diagnosis of EOP, which occurs far less commonly than that of solitary plasmacytoma of the bone ([@b1-mco-0-0-1417]), is determined based on the identification of a localised tumour comprising monoclonal plasma cells, which are identical to those observed in multiple myeloma; however, EOP is distinguished by an absence of indicators of the disseminated form of disease, such as additional lesions detected on skeletal radiological imaging, the presence of bone marrow plasmacytosis, and the presence of anaemia, hypercalcaemia, or renal failure, as was the case for the current patient. Solitary primary EOP is rare, and is predominantly diagnosed in elderly individuals ([@b4-mco-0-0-1417],[@b13-mco-0-0-1417],[@b15-mco-0-0-1417]). EOP occurs most often in the head and neck area, and tends to involve the submucosal tissues of the upper respiratory tract, accounting for \~0.5% of all neoplasms that occur at this location. Involvement of the parotid gland is extremely rare, as evidenced by the fact that only 19 cases ([Table I](#tI-mco-0-0-1417){ref-type="table"}) ([@b3-mco-0-0-1417]--[@b20-mco-0-0-1417]) have been previously documented in the published literature, including the first case described in 1965 by Vainio-Mattila ([@b3-mco-0-0-1417]). Although the current literature review suggested that parotid gland EOP has a favourable prognosis, assuming that multiple myeloma has been ruled out, the clinical behaviour of this disease is not well understood. The conversion rate of solitary EOP to solitary plasmacytoma of the bone is 48%, while that of EOP to multiple myeloma is 20%, both of which are associated with a poorer prognosis ([@b1-mco-0-0-1417],[@b2-mco-0-0-1417],[@b20-mco-0-0-1417]). A definitive diagnosis of parotid EOP cannot be established solely by preoperative investigations, as demonstrated in the present case; however, it remains important to recognise this distinctive type of plasmacytoma confined to the parotid area, in order to avoid confusion with other parotid benign lesions/reactive enlargements that have a similar appearance.

As mentioned previously, histopathological analysis in isolation is insufficient to confirm a diagnosis of primary extramedullary plasmacytoma, since it is necessary to exclude the possibility of multiple myeloma through skeletal and marrow examinations, immunoelectrophoresis, quantitative immunoglobulin testing, and confirmation of the absence of urinary Bence Jones proteins ([@b17-mco-0-0-1417]). Cyclin D1 expression in EOP, as observed in the current patient, has been associated with an unfavourable prognosis in previous studies ([@b19-mco-0-0-1417]); however, this did not seem to be true of the present case. In addition, the distinction between plasmacytoma and lymphoma with extreme plasma cell differentiation may be challenging ([@b1-mco-0-0-1417],[@b2-mco-0-0-1417]).

The treatment of solitary extramedullary plasmacytoma should consist primarily of eradication of the lesion locally, and surgery therefore appears to be the primary line of treatment. Radiation therapy has also been used in some cases, either alone in patients deemed unsuitable for surgery, or as an adjunct to the surgical removal of the lesion in order to prevent local relapse, as in the current case. The rates of conversion of solitary EOP to solitary plasmacytoma of the bone and to multiple myeloma are 48 and 20%, respectively, and both are associated with a poorer prognosis ([@b1-mco-0-0-1417]--[@b20-mco-0-0-1417]). Although not scientifically validated, chemotherapy is theoretically advantageous: As well as augmenting local control of the neoplasm, it may potentially eradicate sub-clinical disease, delaying or preventing the development of myeloma ([@b2-mco-0-0-1417]). Patterns of primary extramedullary plasmacytoma relapse include local recurrence, transformation to multiple myeloma, and metastasis. Recurrences are typically localized and respond well to radiotherapy. Combined chemotherapy and radiation therapy is recommended for high-risk surgical patients (ASA physical status classification system category ≥3), to increase the rates of local control and cure ([@b2-mco-0-0-1417],[@b18-mco-0-0-1417]--[@b20-mco-0-0-1417]).

In summary, although patients with parotid enlargements are commonly observed in everyday clinical practice, EOP arising in the parotid gland is extremely rare. Fine-needle aspiration cytology, histopathological examination, immunohistochemical analysis, and an absence of signs indicating disseminated disease aid in providing an accurate diagnosis and treatment. EOP should be considered in the differential diagnosis of parotid tumours.

![Clinical appearance of the parotid region in the right retroauricular area (arrow) of a patient with a 3-month history of a painless lesion that gradually increased in size.](mco-07-05-0751-g00){#f1-mco-0-0-1417}

![Magnetic resonance imaging of the head and neck demonstrated a right parotid tail mass, measuring 3×3×3 cm. The mass was round, with well-defined contours, and was hypointense on T1 and T2 sequences and hyperintense on the T2-STIR sequence in the superficial portion of the right parotid gland (arrow).](mco-07-05-0751-g01){#f2-mco-0-0-1417}

![Haematoxylin and eosin staining revealed diffuse plasmacytic proliferation among residual reactive lymphoid follicles, with minimal pleomorphism (a number of large nuclei and binucleated cells). Original magnification, ×100.](mco-07-05-0751-g02){#f3-mco-0-0-1417}

![Immunohistochemical staining revealed monotypic λ light chain restriction.](mco-07-05-0751-g03){#f4-mco-0-0-1417}

![Immunohistochemical staining revealed nuclear expression of cyclin D1.](mco-07-05-0751-g04){#f5-mco-0-0-1417}

###### 

Overview of published cases of parotid extraosseous plasmacytoma.

  Authors, year             Age/sex   Side    Treatment     (Refs.)
  ------------------------- --------- ------- ------------- -----------------------
  Vainio-Mattila            74/F      Left    S + RT        ([@b3-mco-0-0-1417])
  Pahor                     61/F      Left    S + CT + RT   ([@b4-mco-0-0-1417])
                            69/M      Right   S + CT + RT   
  Ferlito *et al*           47/M      Left    S + RT + CT   ([@b5-mco-0-0-1417])
  Kurihara and Hashimoto    61/F      Right   S             ([@b6-mco-0-0-1417])
  Edney *et al*             38/M      Right   S             ([@b7-mco-0-0-1417])
  Kanoh *et al*             78/F      Left    S + RT        ([@b8-mco-0-0-1417])
  Ebbers                    68/M      Right   RT            ([@b9-mco-0-0-1417])
  Scholl and Jafek          60/F      Left    S             ([@b10-mco-0-0-1417])
  Simi *et al*              58/M      Right   S             ([@b11-mco-0-0-1417])
  Rothfield *et al*         53/M      Left    S             ([@b12-mco-0-0-1417])
  Kerr and Dort             73/F      Right   S + RT        ([@b13-mco-0-0-1417])
  El-Naggar *et al*         73/M      Left    S             ([@b14-mco-0-0-1417])
  Gonzalez-Garcia *et al*   63/M      Right   S + RT        ([@b15-mco-0-0-1417])
  Hari and Roblin           60/F      Right   S             ([@b16-mco-0-0-1417])
  Ustun *et al*             77/F      Left    S + RT        ([@b17-mco-0-0-1417])
  Kanthan and Torkian       73/F      Right   S + RT + CT   ([@b18-mco-0-0-1417])
  Gouveris *et al*          76/M      Left    RT            ([@b19-mco-0-0-1417])
  Alabed *et al*            75/F      Left    RT            ([@b20-mco-0-0-1417])
  Our case                  47/M      Right   S+RT          --

S, surgery; RT, radiotherapy; CT, chemotherapy.
